Overview
Start/End Dates
Locations
Gordon and Leslie Diamond Health Care Centre
Vancouver General Hospital
Name/Title
Sydney Thorsteinsson, Cardiology Research Coordinator
Phone
Email Address
Purpose of Study
The purpose of this study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major cardiovascular events when initiated as soon as possible in adult patients who have had a heart attack. Ziltivekimab is a medication designed to reduce inflammation after a heart attack, and thereby reduce secondary cardiac events.
Patients eligible for the ARTEMIS study will be enrolled within 48-36 hours of their heart attack. Enrolled patients will have blood work drawn, complete assessments and start on the loading dose of Ziltivekimab while in hospital. One month later, the patient will return to the clinic and learn how to complete self-injections at home. The patient will return to the clinic roughly every three months for additional bloodwork, assessments and be re-supplied with the study medication to inject at home.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
The purpose of this study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major cardiovascular events when initiated as soon as possible in adult patients who have had a heart attack. Ziltivekimab is a medication designed to reduce inflammation after a heart attack, and thereby reduce secondary cardiac events.
Patients eligible for the ARTEMIS study will be enrolled within 48-36 hours of their heart attack. Enrolled patients will have blood work drawn, complete assessments and start on the loading dose of Ziltivekimab while in hospital. One month later, the patient will return to the clinic and learn how to complete self-injections at home. The patient will return to the clinic roughly every three months for additional bloodwork, assessments and be re-supplied with the study medication to inject at home.
Visit ClinicalTrials.gov for more information.
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
